|
Q2 FY2026
As of Jun 28, 2026
|
Q1 FY2026
As of Mar 29, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 28, 2025
|
Q2 FY2025
As of Jun 29, 2025
|
Q1 FY2025
As of Mar 30, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 29, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Oct 1, 2023
|
Q2 FY2023
As of Jul 2, 2023
|
Q1 FY2023
As of Apr 2, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 25, 2022
|
Q2 FY2022
As of Jun 26, 2022
|
Q1 FY2022
As of Mar 27, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 26, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts and other receivables, net of allowances of $0.5 and $0.5, respectively | ||||||||||||||||||||
| Prepayments and accrued income | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Current assets held-for-sale | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Non-current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Right-of-use assets from operating leases | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangibles, net | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Pensions and other retirement benefits | ||||||||||||||||||||
| Investments and loans to joint ventures and other affiliates | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Current maturities of long-term debt and short-term borrowings | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Taxes on income | ||||||||||||||||||||
| Current liabilities held-for-sale | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Pensions and other retirement benefits | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity | ||||||||||||||||||||
| Ordinary shares of £0.50 par value; authorized 40,000,000 shares for 2026 and 2025; issued 28,944,000 for 2026 and 2025; outstanding 26,759,241 and 26,640,434 for 2026 and 2025, respectively | ||||||||||||||||||||
| Ordinary shares | ||||||||||||||||||||
| Total ordinary shares of £0.50 par value; authorized 40,000,000 shares for 2026 and 2025; issued 28,944,000 for 2026 and 2025; outstanding 26,759,241 and 26,640,434 for 2026 and 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury shares | ||||||||||||||||||||
| Company shares held by ESOP | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity | ||||||||||||||||||||
| Common stock, shares outstanding (in shares) | ||||||||||||||||||||
| Ordinary shares | ||||||||||||||||||||
| Total common stock, shares outstanding (in shares) | ||||||||||||||||||||
| Common stock, shares issued (in shares) | ||||||||||||||||||||
| Ordinary shares | ||||||||||||||||||||
| Total common stock, shares issued (in shares) | ||||||||||||||||||||
Loading...
